The Neuromuscular Disorders drugs in development market research report provides comprehensive information on the therapeutics under development for Neuromuscular Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Neuromuscular Disorders. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Neuromuscular Disorders and features dormant and discontinued products.
GlobalData tracks 48 drugs in development for Neuromuscular Disorders by 35 companies/universities/institutes. The top development phase for Neuromuscular Disorders is discovery with 24 drugs in that stage. The Neuromuscular Disorders pipeline has 46 drugs in development by companies and two by universities/ institutes. Some of the companies in the Neuromuscular Disorders pipeline products market are: StrideBio, Sarepta Therapeutics and Ascidian Therapeutics.
The key targets in the Neuromuscular Disorders pipeline products market include Muscle Skeletal Receptor Tyrosine Protein Kinase, Chloride Channel Protein 1, and Acetylcholinesterase Collagenic Tail Peptide.
The key mechanisms of action in the Neuromuscular Disorders pipeline product include Muscle Skeletal Receptor Tyrosine Protein Kinase Activator with two drugs in Phase I. The Neuromuscular Disorders pipeline products include seven routes of administration with the top ROA being Intravenous and ten key molecule types in the Neuromuscular Disorders pipeline products market including Gene Therapy, and Monoclonal Antibody.
Neuromuscular Disorders overview
Neuromuscular disorders are conditions that affect the function of the nerves and muscles in the body. They can cause muscle weakness, fatigue, pain, spasms, and other symptoms. Neuromuscular disorders can be inherited or acquired, and they can affect different parts of the neuromuscular system, such as the peripheral nerves, the skeletal muscles, or the neuromuscular junction. Some examples of neuromuscular disorders are amyotrophic lateral sclerosis (ALS), myasthenia gravis, muscular dystrophy, and Guillain-Barré syndrome. Neuromuscular disorders are diagnosed by clinical examination, electrodiagnostic studies, blood tests, genetic tests, and muscle biopsy. Treatment options depend on the type and severity of the disorder, and may include medication, surgery, physical therapy, occupational therapy, and supportive care. The outlook for people with neuromuscular disorders varies depending on the progression and complications of the disease.
For a complete picture of Neuromuscular Disorders’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
